Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 3 clinical trial of VIVITROL® (naltrexone for extended-release injectable suspension) for the treatment of opioid dependence. The multi-center study is designed to assess the efficacy and safety of VIVITROL in approximately 200 patients diagnosed with opioid dependence. The clinical data from this study will form the basis of a supplemental New Drug Application (sNDA) to the U.S.

More: continued here

This entry was posted on Friday, July 4th, 2008 at 2:07 pm and is filed under Alcohol / Addiction / Illegal Drugs. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.